A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

导出 OA

翻译打印收藏纠错

作者： Yiling,Jiang ^[1] ; Lori D,Bash ^[2] ; Leif,Saager ^[3]

作者单位： Center for Observational and Real-world Evidence (CORE), Merck Sharp & Dohme (UK) Ltd., 120 Moorgate, London, EC2Y 9AL, UK. yiling.jiang1@msd.com. ^[1] Center for Observational and Real-world Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA. ^[2] Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA. ^[3] Klinik fuer Anaesthesiologie Universitaetsmedizin Goettingen, Goettingen, Germany. ^[4]

关键词 Bridion Budget impact Cost Neuromuscular blockade Post-operative complications Sugammadex

主题词成年人(Adult);人类(Humans);新斯的明(Neostigmine);神经肌肉阻滞(Neuromuscular Blockade);神经肌肉非去极药(Neuromuscular Nondepolarizing Agents);γ环糊精类(gamma-Cyclodextrins)

DOI 10.1007/s12325-021-01701-1

PMID 33871823

发布时间 2024-04-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交